Lipid-Lowering Therapy After Coronary Revascularization: The Interventional Cardiologist’s Perspective 11This work was supported by the Cardiology Research Foundation, Washington, DC.

There is now a very large number of patients with coronary artery disease who have also undergone percutaneous interventions such as coronary angioplasty. Atherosclerosis and restenosis are two distinct pathologic processes with different underlying pathophysiologic mechanisms, different natural histories, different clinical presentations, and treatment strategies. Management strategies to target both processes are currently poorly applied in clinical practice. The development of integrated management strategies to target atherosclerosis, as well as restenosis in the postprocedural period remains a priority.

show abstract

Pathophysiology of atherosclerosis: Development, regression, restenosis

Adams

Kinlay

Blake

et al. 2000

Curr Atheroscler Rep

View full text Add to dashboard Cite

show abstract

The comparative pathobiology of atherosclerosis and restenosis

Orford

Selwyn

Ganz

et al. 2000

The American Journal of Cardiology

121

View full text Add to dashboard Cite

Clinical trials in interventional cardiology

Popma

Piana²,

Prpic³

1999

Current Opinion in Cardiology

View full text Add to dashboard Cite

Several well-designed, randomized trials and registries have recently been completed in patients undergoing percutaneous coronary intervention (PCI) for the treatment of symptomatic coronary artery disease. These studies have further clarified the value of newer pharmacologic and mechanical approaches to patients with atherosclerotic disease and have resulted in improved clinical outcomes in patients undergoing PCI. As a result, many of the older paradigms of lesion-specific device selection have been revised to include the intricate balance of devices and drugs, tailored to the specific clinical presentation and lesion morphology in patients undergoing PCI. This article reviews several recent clinical trials and discusses their impact on early and late outcomes in patients undergoing PCI for symptomatic coronary artery disease.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lipid-Lowering Therapy After Coronary Revascularization: The Interventional Cardiologist’s Perspective 11This work was supported by the Cardiology Research Foundation, Washington, DC.

Cited by 4 publications

References 70 publications

Pathophysiology of atherosclerosis: Development, regression, restenosis

Pathophysiology of atherosclerosis: Development, regression, restenosis

The comparative pathobiology of atherosclerosis and restenosis

Clinical trials in interventional cardiology

Contact Info

Product

Resources

About